Vertex Pharmaceuticals Incorporated (LON: 0QZU)
London
· Delayed Price · Currency is GBP · Price in USD
395.63
0.00 (0.00%)
At close: Dec 23, 2024
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending September 29, 2024, with 11.61% growth. This brings the company's revenue in the last twelve months to $10.63B, up 10.06% year-over-year. In the year 2023, Vertex Pharmaceuticals had annual revenue of $9.87B with 10.51% growth.
Revenue (ttm)
$10.63B
Revenue Growth
+10.06%
P/S Ratio
n/a
Revenue / Employee
$1.97M
Employees
5,400
Market Cap
81.38B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 9.87B | 938.50M | 10.51% |
Dec 30, 2022 | 8.93B | 1.36B | 17.91% |
Dec 30, 2021 | 7.57B | 1.37B | 22.06% |
Dec 30, 2020 | 6.21B | 2.04B | 49.08% |
Dec 30, 2019 | 4.16B | 1.12B | 36.59% |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 30, 2016 | Pro | Pro | Pro |
Dec 30, 2015 | Pro | Pro | Pro |
Dec 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVertex Pharmaceuticals News
- 3 hours ago - Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst - Benzinga
- 3 hours ago - Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst - Benzinga
- 3 hours ago - Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
- 6 hours ago - Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky - Accesswire
- 1 day ago - Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio? - Benzinga
- 1 day ago - Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? - The Motley Fool
- 2 days ago - Vertex wins approval of new cystic fibrosis therapy Alyftrek - Seeking Alpha
- 2 days ago - Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK⢠- GuruFocus